Nobel Laureate is Demanding More Money from Ono Pharma for Cancer Drug
16 April 2019
Nobel laureate Tasuku Honjo said Wednesday he is involved in a dispute over license fees under a patent agreement with Ono Pharmaceutical Co., which sells a cancer treatment drug developed based on his research.
Russian Drug Maker Gains World’s First Approval for Biosimilar Eculizumab
15 April 2019
Russian drug manufacturer Generium Pharmaceutical, which specializes in orphan drugs, announced yesterday that it has received Russian marketing approval for its biosimilar eculizumab, referencing Soliris, the most expensive orphan drug in Russia.
Method of Price Registration in Russia
15 April 2019
The state policy on medicine and medical products circulation was discussed at the XI All-Russian Congress of the Pharmaceutical and Medical Industries. “Unfortunately, current trend is to tie all issues in the pharmaceutical industry with regulating medical prices”, started her speech Deputy Head of FAS Department for Control over Social Sphere and Trade, Nadezhda Sharavskaya. She pointed out that “competences of the pharmaceutical companies are formed today based on the artificial media hype rather than the valid and the RIA projects”.
aunching of Russian Vaccines in Latin America
12 April 2019
MECHNIKOV Institute has launched the production of commercial vaccine batches in Managua (Nicaragua). The launch of the production lines was attended by the advisor for investments of the Government of Nicaragua Laureano Ortega, Deputy Minister of Health of the Russian Federation Sergey Kraevoy, President of the Nicaraguan Institute of Social Insurance Dr. Roberto Lopez, Head of Federal medical and biological agency of Russia (FMBA) Viktor Uiba and Director of the Saint-Petersburg scientific research institute of vaccines and serums of the FMBA of Russia (SPbSRIVS) Viktor Trukhin. The project has been implemented pursuant to the Instruction of Vladimir Putin, the President of the Russian Federation.
New Track-and-Trace System in Russia
12 April 2019
Christoph Krähenbühl, senior director of Excellis Europe, explains the challenge the new Russian traceability regulations present to the pharma industry, and how all participants in the supply chain must properly prepare to ensure that they become compliant within this new environment.
Diabetic foot treatment supported
11 April 2019
Russia’s Skolkovo Foundation and Human Stem Cells Institute (HSCI), a private holding company, are supporting a young Russian company called NextGene, a Skolkovo resident. Of the $492,000 grant funding, an estimated $246,000 should come from Skolkovo and HSCI is expected to match the amount, the Skolkovo Foundation website announced .
Nanoparticles for normal blood pressure
10 April 2019
Biologists in Novosibirsk, in Siberia, have developed special nanoparticles that are said to be able to lower blood pressure, and are reported to have successfully tested the drug candidate on hypertension afflicted rats.
Announcing of Formulary of Russian Pharmaceutical Manufacturers
10 April 2019
At the 2nd conference «Information technologies in pharmacy: the pharamceutical industry on its way to digital transformation», SID & GP announced drafting of the Formulary of Russian pharmaceutical manufacturers. It has appeared that such a summary digest with the data allowing for an unbiassed assessment of the industry is much in demand by pharmaceutical companies.
Going Global in Biopharma Regulatory Affairs
09 April 2019
The biopharmaceutical regulatory landscape is continually shifting and adapting, mirroring the innovative nature of the industry and ultimately ensuring the safety of all stakeholders. With increasing demands for globally accepted solutions to mitigate the rising development costs, further regulatory harmonization would undoubtedly be beneficial to patients and manufacturers.
New Class of Drugs to Stop Growing of Ovarian Cancer Cells
09 April 2019
A team of researchers across The University of Manchester have shown that a new class of drugs are able to stop ovarian cancer cells growing.The Cancer Research UK and Wellcome Trust funded study, published in the journal Cancer Cell, showed that the drugs, called PARG inhibitors, can kill ovarian cancer cells by targeting weaknesses within their ability to copy their DNA.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Four cancer centers opened in Russia in 2023
26 April 2024
Russia and the UAE can simplify the drug registration process
26 April 2024
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024